메뉴 건너뛰기




Volumn 13, Issue 2, 2013, Pages 283-294

Contemporary use of bevacizumab in ovarian cancer

Author keywords

adverse event; angiogenesis; bevacizumab; chemotherapy; clinical trial; ovarian cancer; primary ovarian cancer; recurrent ovarian cancer; review; treatment

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

EID: 84872202099     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.745508     Document Type: Article
Times cited : (13)

References (56)
  • 2
    • 0036498788 scopus 로고    scopus 로고
    • Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
    • DOI 10.1200/JCO.20.5.1248
    • Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-Analysis. J Clin Oncol 2002;120(5):1248-59 (Pubitemid 34177431)
    • (2002) Journal of Clinical Oncology , vol.20 , Issue.5 , pp. 1248-1259
    • Bristow, R.E.1    Tomacruz, R.S.2    Armstrong, D.K.3    Trimble, E.L.4    Montz, F.J.5
  • 3
    • 77950349922 scopus 로고    scopus 로고
    • Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: From platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds
    • Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009;19(Suppl 2):S63-7
    • (2009) Int J Gynecol Cancer , vol.19 , Issue.SUPPL. 2
    • Monk, B.J.1    Coleman, R.L.2
  • 4
    • 84857579960 scopus 로고    scopus 로고
    • Moleculargenetic therapies in ovarian cancer: Future opportunities and challenges
    • Ziebarth AJ, Landen CN Jr., Alvarez RD. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol 2012;55(1):156-72
    • (2012) Clin Obstet Gynecol , vol.55 , Issue.1 , pp. 156-72
    • Ziebarth, A.J.1    Landen Jr., C.N.2    Alvarez, R.D.3
  • 5
    • 81255188940 scopus 로고    scopus 로고
    • Tumor angiogenesis: Molecular pathways and therapeutic targets
    • Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17(11):1359-70
    • (2011) Nat Med , vol.17 , Issue.11 , pp. 1359-70
    • Weis, S.M.1    Cheresh, D.A.2
  • 6
    • 30944446883 scopus 로고    scopus 로고
    • Lessons from phase III clinical trials on anti-VEGF therapy for cancer
    • DOI 10.1038/ncponc0403, PII N0403
    • Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40 (Pubitemid 43108832)
    • (2006) Nature Clinical Practice Oncology , vol.3 , Issue.1 , pp. 24-40
    • Jain, R.K.1    Duda, D.G.2    Clark, J.W.3    Loeffler, J.S.4
  • 7
    • 79956328903 scopus 로고    scopus 로고
    • Molecular mechanisms and clinical applications of angiogenesis
    • 19473
    • Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;19473(7347):298-307
    • (2011) Nature , Issue.7347 , pp. 298-307
    • Carmeliet, P.1    Jain, R.K.2
  • 8
    • 84872172744 scopus 로고    scopus 로고
    • Angiogenesis inhibitors. National Cancer Institute at the National Institutes of health. Bethesda, MD. Available from:
    • Angiogenesis inhibitors. National Cancer Institute at the National Institutes of health. Bethesda, MD. Available from: http://www.cancer.gov/ cancertopics/factsheet/Therapy/angiogenesis-inhibitors
  • 9
    • 79951988792 scopus 로고    scopus 로고
    • Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A gynecologic oncology group trial
    • Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011;129(1):69-74
    • (2011) J Clin Oncol , vol.129 , Issue.1 , pp. 69-74
    • Matei, D.1    Sill, M.W.2    Lankes, H.A.3
  • 10
    • 79251585977 scopus 로고    scopus 로고
    • A phase ii study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An ncic clinical trials group study
    • Biagi JJ, Oza AM, Chalchal HI, et al. A Phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011;22(2):335-40
    • (2011) Ann Oncol , vol.22 , Issue.2 , pp. 335-40
    • Biagi, J.J.1    Oza, A.M.2    Chalchal, H.I.3
  • 11
    • 73949123481 scopus 로고    scopus 로고
    • Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer
    • Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;2027(33):5601-6
    • (2009) J Clin Oncol , vol.2027 , Issue.33 , pp. 5601-6
    • Matulonis, U.A.1    Berlin, S.2    Ivy, P.3
  • 12
    • 77956649079 scopus 로고    scopus 로고
    • A phase ii open-label study evaluating pazopanib in patients with recurrent ovarian cancer
    • Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32-7
    • (2010) Gynecol Oncol , vol.119 , Issue.1 , pp. 32-7
    • Friedlander, M.1    Hancock, K.C.2    Rischin, D.3
  • 13
    • 0015311426 scopus 로고
    • Anti-Angiogenesis: New concept for therapy of solid tumors
    • Folkman J. Anti-Angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175(3):409-16
    • (1972) Ann Surg , vol.175 , Issue.3 , pp. 409-16
    • Folkman, J.1
  • 14
    • 0030512608 scopus 로고    scopus 로고
    • Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
    • Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;32A(14):2386-93
    • (1996) Eur J Cancer , vol.32 A , Issue.14 , pp. 2386-93
    • Hanahan, D.1    Christofori, G.2    Naik, P.3    Arbeit, J.4
  • 15
    • 0036782278 scopus 로고    scopus 로고
    • VEGF and the quest for tumour angiogenesis factors
    • DOI 10.1038/nrc909
    • Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2(10):795-803 (Pubitemid 37328914)
    • (2002) Nature Reviews Cancer , vol.2 , Issue.10 , pp. 795-803
    • Ferrara, N.1
  • 16
    • 14644440555 scopus 로고    scopus 로고
    • Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    • DOI 10.1200/JCO.2005.06.081
    • Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;1023(5):1011-27 (Pubitemid 46202320)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.5 , pp. 1011-1027
    • Hicklin, D.J.1    Ellis, L.M.2
  • 17
    • 63749125392 scopus 로고    scopus 로고
    • Vegfs and receptors involved in angiogenesis versus lymphangiogenesis
    • Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21(2):154-64
    • (2009) Curr Opin Cell Biol , vol.21 , Issue.2 , pp. 154-64
    • Lohela, M.1    Bry, M.2    Tammela, T.3    Alitalo, K.4
  • 18
    • 80052015813 scopus 로고    scopus 로고
    • Molecular control of endothelial cell behaviour during blood vessel morphogenesis
    • Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011;12(9):551-64
    • (2011) Nat Rev Mol Cell Biol , vol.12 , Issue.9 , pp. 551-64
    • Herbert, S.P.1    Stainier, D.Y.2
  • 19
    • 43249095919 scopus 로고    scopus 로고
    • Tumor angiogenesis
    • DOI 10.1056/NEJMra0706596
    • Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;8358(19):2039-49 (Pubitemid 351656458)
    • (2008) New England Journal of Medicine , vol.358 , Issue.19 , pp. 2039-2049
    • Kerbel, R.S.1
  • 20
    • 0036780251 scopus 로고    scopus 로고
    • Clinical translation of angiogenesis inhibitors
    • DOI 10.1038/nrc905
    • Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2(10):727-39 (Pubitemid 37328908)
    • (2002) Nature Reviews Cancer , vol.2 , Issue.10 , pp. 727-739
    • Kerbel, R.1    Folkman, J.2
  • 21
    • 0034306969 scopus 로고    scopus 로고
    • Blockade of nuclear factor-kappab signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8
    • Huang S, Robinson JB, Deguzman A, et al. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;160(19):5334-9
    • (2000) Cancer Res , vol.160 , Issue.19 , pp. 5334-9
    • Huang, S.1    Robinson, J.B.2    Deguzman, A.3
  • 22
    • 84870313971 scopus 로고    scopus 로고
    • Angiogenesis: A promising therapeutic target for ovarian cancer
    • Epub ahead of print
    • Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol 2012; Epub ahead of print
    • (2012) Crit Rev Oncol Hematol
    • Bamias, A.1    Pignata, S.2    Pujade-Lauraine, E.3
  • 23
    • 84858200516 scopus 로고    scopus 로고
    • Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer
    • Teoh D, Secord AA. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int J Gynecol Cancer 2012;22(3):348-59
    • (2012) Int J Gynecol Cancer , vol.22 , Issue.3 , pp. 348-59
    • Teoh, D.1    Secord, A.A.2
  • 24
    • 13444278498 scopus 로고    scopus 로고
    • Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    • Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;165(3):671-80 (Pubitemid 40216420)
    • (2005) Cancer Research , vol.65 , Issue.3 , pp. 671-680
    • Gerber, H.-P.1    Ferrara, N.2
  • 25
    • 3042643346 scopus 로고    scopus 로고
    • Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies
    • DOI 10.1345/aph.1D470
    • Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004;38(7-8):1258-64 (Pubitemid 38802172)
    • (2004) Annals of Pharmacotherapy , vol.38 , Issue.7-8 , pp. 1258-1264
    • Zondor, S.D.1    Medina, P.J.2
  • 26
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • DOI 10.1126/science.1104819
    • Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;7307(5706):58-62 (Pubitemid 40093472)
    • (2005) Science , vol.307 , Issue.5706 , pp. 58-62
    • Jain, R.K.1
  • 27
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study
    • DOI 10.1200/JCO.2007.11.5345
    • Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;2025(33):5165-71 (Pubitemid 350237599)
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.33 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 29
    • 37849035249 scopus 로고    scopus 로고
    • Phase ii clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the california, chicago, and princess margaret hospital phase ii consortia
    • Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26(1):76-82
    • (2008) J Clin Oncol , vol.26 , Issue.1 , pp. 76-82
    • Garcia, A.A.1    Hirte, H.2    Fleming, G.3
  • 30
    • 79957949444 scopus 로고    scopus 로고
    • Phase ii trial of bevacizumab in recurrent or persistent endometrial cancer: A gynecologic oncology group study
    • Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;129(16):2259-64
    • (2011) J Clin Oncol , vol.129 , Issue.16 , pp. 2259-64
    • Aghajanian, C.1    Sill, M.W.2    Darcy, K.M.3
  • 31
    • 61549141361 scopus 로고    scopus 로고
    • Phase ii trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study
    • Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009;127(7):1069-74
    • (2009) J Clin Oncol , vol.127 , Issue.7 , pp. 1069-74
    • Monk, B.J.1    Sill, M.W.2    Burger, R.A.3
  • 32
    • 13844266766 scopus 로고    scopus 로고
    • Activity of bevacizumab (rhumab vegf) in advanced refractory epithelial ovarian cancer
    • Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96(3):902-4
    • (2005) Gynecol Oncol , vol.96 , Issue.3 , pp. 902-4
    • Monk, B.J.1    Choi, D.C.2    Pugmire, G.3    Burger, R.A.4
  • 33
    • 80051549914 scopus 로고    scopus 로고
    • Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian peritoneal or fallopian tube cancer: Results of a phase 2 study
    • 15117
    • McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011;15117(16):3731-40
    • (2011) Cancer , Issue.16 , pp. 3731-40
    • McGonigle, K.F.1    Muntz, H.G.2    Vuky, J.3
  • 34
    • 84864396971 scopus 로고    scopus 로고
    • A phase ii clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian fallopian tube or primary peritoneal cancer
    • Del Carmen MG, Micha J, Small L, et al. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 2012;126(3):369-74
    • (2012) Gynecol Oncol , vol.126 , Issue.3 , pp. 369-74
    • Del Carmen, M.G.1    Micha, J.2    Small, L.3
  • 36
    • 70350566692 scopus 로고    scopus 로고
    • Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
    • Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009;115(3):396-400
    • (2009) Gynecol Oncol , vol.115 , Issue.3 , pp. 396-400
    • Hurt, J.D.1    Richardson, D.L.2    Seamon, L.G.3
  • 37
    • 79955477996 scopus 로고    scopus 로고
    • Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    • O'Malley DM, Richardson DL, Rheaume PS, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011;1121(2):269-72
    • (2011) Gynecol Oncol , vol.1121 , Issue.2 , pp. 269-72
    • O'Malley, D.M.1    Richardson, D.L.2    Rheaume, P.S.3
  • 38
    • 84872199175 scopus 로고    scopus 로고
    • Safety of front-line bevacizumab (bev) combined with weekly paclitaxel (wpac) and q3w carboplatin (c) for ovarian cancer (oc): Results from octavia
    • abstract 5017
    • Gonzalez-Martin A, Gladieff L, Tholander B, et al. Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): results from OCTAVIA. J Clin Oncol 2012;30(Suppl):abstract 5017
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Gonzalez-Martin, A.1    Gladieff, L.2    Tholander, B.3
  • 39
    • 84855425106 scopus 로고    scopus 로고
    • Incorporation of bevacizumab in the primary treatment of ovarian cancer
    • 29365
    • Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;29365(26):2473-83
    • (2011) N Engl J Med , Issue.26 , pp. 2473-83
    • Burger, R.A.1    Brady, M.F.2    Bookman, M.A.3
  • 40
    • 84855466019 scopus 로고    scopus 로고
    • A phase 3 trial of bevacizumab in ovarian cancer
    • 29365
    • Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;29365(26):2484-96
    • (2011) N Engl J Med , Issue.26 , pp. 2484-96
    • Perren, T.J.1    Swart, A.M.2    Pfisterer, J.3
  • 41
    • 84861736119 scopus 로고    scopus 로고
    • Oceans: A randomized, double-blind, placebo-controlled phase iii trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    • These results suggest that the risk of GIP seems to be in line with prescribing information when the number of prior chemotherapy regimens is restricted to two or fewer
    • Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;1030(17):2039-44 .. These results suggest that the risk of GIP seems to be in line with prescribing information when the number of prior chemotherapy regimens is restricted to two or fewer.
    • (2012) J Clin Oncol , vol.1030 , Issue.17 , pp. 2039-44
    • Aghajanian, C.1    Blank, S.V.2    Goff, B.A.3
  • 42
    • 84872175305 scopus 로고    scopus 로고
    • Gynecological cancers 967oupdated overall survival analysis in oceans a randomized phase 3 trial of gemcitabine (g) + carboplatin (c) and bevacizumab (bv) or placebo (pl) followed by bv or pl in platinum-sensitive recurrent epithelial ovarian (roc) primary peritoneal (ppc) or fallopian tube cancer (ftc)
    • Aghajanian C, Nycum LR, Goff B, et al. Gynecological cancers/967OUpdated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Ann Oncol 2012;23(Suppl 9):ix319
    • (2012) Ann Oncol , vol.23 , Issue.SUPPL. 9
    • Aghajanian, C.1    Nycum, L.R.2    Goff, B.3
  • 43
    • 84866493383 scopus 로고    scopus 로고
    • Aurelia: A randomized phase iii trial evaluating bevacizumab (bev) plus chemotherapy (ct) for platinum (pt)- resistant recurrent ovarian cancer (oc)
    • abstract LBA5002 .These results suggest that the risk of GIP seems to be in line with prescribing information when the number of prior chemotherapy regimens is restricted to two or fewer
    • Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)- resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl): abstract LBA5002 .These results suggest that the risk of GIP seems to be in line with prescribing information when the number of prior chemotherapy regimens is restricted to two or fewer.
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Pujade-Lauraine, E.1    Hilpert, F.2    Weber, B.3
  • 44
    • 84872196870 scopus 로고    scopus 로고
    • Phase ii trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    • abstract 5013
    • Hagemann AR, Zighelboim I, Novetsky AP, et al. Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30(Suppl): abstract 5013
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Hagemann, A.R.1    Zighelboim, I.2    Novetsky, A.P.3
  • 45
    • 84872836407 scopus 로고    scopus 로고
    • Phase ii clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
    • Epub ahead of print]
    • Tillmanns TD, Lowe MP, Walker MS, et al. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 2012; [Epub ahead of print]
    • (2012) Gynecol Oncol
    • Tillmanns, T.D.1    Lowe, M.P.2    Walker, M.S.3
  • 46
    • 80052564414 scopus 로고    scopus 로고
    • Plasma biomarker analysis in the avado phase iii randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (her) 2-negative metastatic breast cancer
    • Abstract P2-16-04
    • Miles D, Haas SD, Dirix L, et al. Plasma biomarker analysis in the AVADO phase III randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer. Cancer Res 2010;70:24 Suppl 2:Abstract P2-16-04
    • (2010) Cancer Res , vol.70 , Issue.24 SUPPL. 2
    • Miles, D.1    Haas, S.D.2    Dirix, L.3
  • 47
    • 84863897798 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the avagast randomized phase iii trial
    • Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;1030(17):2119-27
    • (2012) J Clin Oncol , vol.1030 , Issue.17 , pp. 2119-27
    • Van Cutsem, E.1    De Haas, S.2    Kang, Y.K.3
  • 48
    • 84863092492 scopus 로고    scopus 로고
    • Vegf pathway genetic variants as biomarkers of treatment outcome with bevacizumab: An analysis of data from the avita and avoren randomised trials
    • Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13(7):724-33
    • (2012) Lancet Oncol , vol.13 , Issue.7 , pp. 724-33
    • Lambrechts, D.1    Claes, B.2    Delmar, P.3
  • 49
    • 84872194939 scopus 로고    scopus 로고
    • Biomarkers 198 biomarker results from gog-0218 a phase iii trial of front-line bevacizumab plus chemotherapy for ovarian cancer
    • This is the first biomarker analysis of bevacizumab trial in ovarian cancer patients.
    • Birrer MJ, Lankes H, Burger RA, et al. Biomarkers/198 Biomarker results from GOG-0218, a phase III trial of front-line bevacizumab plus chemotherapy for ovarian cancer. Ann Oncol 2012;2012;23(Suppl 9):ix81-2 This is the first biomarker analysis of bevacizumab trial in ovarian cancer patients.
    • (2012) Ann Oncol , vol.2012 , Issue.23 SUPPL. 9
    • Birrer, M.J.1    Lankes, H.2    Burger, R.A.3
  • 50
    • 81255185158 scopus 로고    scopus 로고
    • Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
    • Coleman RL, Duska LR, Ramirez PT, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011;12(12):1109-17
    • (2011) Lancet Oncol , vol.12 , Issue.12 , pp. 1109-17
    • Coleman, R.L.1    Duska, L.R.2    Ramirez, P.T.3
  • 51
    • 84872194112 scopus 로고    scopus 로고
    • Prescribing Information Of Avastin Genentech Inc. San Francisco CA. 2012. Available from:
    • Prescribing information of Avastin, Genentech, Inc. San Francisco, CA. 2012.Available from: http://www.gene.com/gene/products/information/pdf/avastin- prescribing.pdf
  • 52
    • 79551520348 scopus 로고    scopus 로고
    • Treatment-related mortality with bevacizumab in cancer patients: A meta-Analysis
    • Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-Analysis. JAMA 2011;2305(5):487-94
    • (2011) JAMA , vol.2305 , Issue.5 , pp. 487-94
    • Ranpura, V.1    Hapani, S.2    Wu, S.3
  • 53
    • 84880829149 scopus 로고    scopus 로고
    • An updated safety analysis of oceans, a randomized, double-blind, phase iii trial of gemcitabine (g) and carboplatin (c) with bevacizumab (bv) or placebo (pl) followed by bv or pl to disease progression (pd) in patients with platinum-sensitive (plat-s) recurrent ovarian cancer
    • abstrACT 5054
    • Aghajanian C, Blank SV, Goff BA, et al. An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer. J Clin Oncol 2012;30(Suppl):abstrACT 5054
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL.
    • Aghajanian, C.1    Blank, S.V.2    Goff, B.A.3
  • 54
    • 79953893326 scopus 로고    scopus 로고
    • At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis
    • Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;129(10):1247-51
    • (2011) J Clin Oncol , vol.129 , Issue.10 , pp. 1247-51
    • Cohn, D.E.1    Kim, K.H.2    Resnick, K.E.3
  • 55
    • 84872175491 scopus 로고    scopus 로고
    • The Cancer Genome Atlas. National Cancer Institute at the National Institutes of Health. Bethesda, MD. Available from:
    • The Cancer Genome Atlas. National Cancer Institute at the National Institutes of Health. Bethesda, MD. Available from: http://cancergenome.nih.gov/
  • 56
    • 71549143528 scopus 로고    scopus 로고
    • Detecting an overall survival benefit that is derived from progression-free survival
    • Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;2101(23):1642-9
    • (2009) J Natl Cancer Inst , vol.2101 , Issue.23 , pp. 1642-9
    • Broglio, K.R.1    Berry, D.A.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.